Cargando…

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma

BACKGROUND: Despite some successes with checkpoint inhibitors for treating cancer, most patients remain refractory to treatment, possibly due to the inhibitory nature of the tumor stroma that impedes the function and entry of effector cells. We devised a new technique of combining immunotherapy with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barsoumian, Hampartsoum B, Ramapriyan, Rishab, Younes, Ahmed I, Caetano, Mauricio S, Menon, Hari, Comeaux, Nathan I, Cushman, Taylor R, Schoenhals, Jonathan E, Cadena, Alexandra P, Reilly, Timothy P, Chen, Dawei, Masrorpour, Fatemeh, Li, Ailin, Hong, David S, Diab, Adi, Nguyen, Quynh-Nhu, Glitza, Isabella, Ferrarotto, Renata, Chun, Stephen G, Cortez, Maria Angelica, Welsh, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592253/ https://www.ncbi.nlm.nih.gov/pubmed/33106386 http://dx.doi.org/10.1136/jitc-2020-000537

Ejemplares similares

Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
por: Menon, Hari, et al.
Publicado: (2019)

Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects
por: Schoenhals, Jonathan E., et al.
Publicado: (2018)

Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy
por: Cortez, Maria Angelica, et al.
Publicado: (2020)

Bone morphogenetic protein 7 promotes resistance to immunotherapy
por: Cortez, Maria Angelica, et al.
Publicado: (2020)

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
por: Menon, Hari, et al.
Publicado: (2019)

Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials
por: Chen, Dawei, et al.
Publicado: (2020)

Radiation and Anti-Cancer Vaccines: A Winning Combination
por: Cadena, Alexandra, et al.
Publicado: (2018)

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
por: Chen, Dawei, et al.
Publicado: (2020)

Radiation Therapy Modulates Tumor Physical Characteristics to Reduce Intratumoral Pressure and Enhance Intratumoral Drug Delivery and Retention
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model
por: Hu, Yun, et al.
Publicado: (2021)

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
por: Welsh, James, et al.
Publicado: (2020)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy
por: Ganjoo, Shonik, et al.
Publicado: (2023)

Pulsed radiotherapy to mitigate high tumor burden and generate immune memory
por: Sezen, Duygu, et al.
Publicado: (2022)

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer
por: Hu, Yun, et al.
Publicado: (2022)

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
por: Bazan-Peregrino, Miriam, et al.
Publicado: (2021)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Toxicity of radiation and immunotherapy combinations
por: Verma, Vivek, et al.
Publicado: (2018)

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2023)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
por: Hu, Yun, et al.
Publicado: (2022)

Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches
por: Klein, Katherine, et al.
Publicado: (2020)

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2023)

Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance
por: Ganjoo, Shonik, et al.
Publicado: (2022)

4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4(+)CD25(+)FoxP3(+) T Regulatory Cell Suppression
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2016)

Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection
por: Hu, Yun, et al.
Publicado: (2023)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_96o4q5ngmj3cjje0nrjoiu2gq3